The Indian edtech sector is entering its consolidation era. Last week, upGrad signed a deal to acquire Unacademy after a year of stretched deliberations. This has become one of the most significant edtech moves after BYJU’S’ $1 Bn acquisition of Aakash in 2021. Let’s unpack the strategic logic behind the acquisition.
upGrad Finds Its Missing Piece: The unicorn spent the past decade building an upskilling stack, but it has always lacked a serious K-12 and test prep engine. Acquiring Unacademy plugs that hole, giving upGrad a large footprint in the segment, minus the need to build the stack from scratch. Unacademy’s $100 Mn cash reserves also help the edtech major cushion its IPO plans in the current tight funding environment.
A Behemoth Emerges: This deal effectively reshapes the competitive landscape. The combined upGrad-Unacademy entity boasted operating revenues of ₹2,400 Cr in FY25, placing it in direct competition with PW’s ₹2,887 Cr in the same period. With BYJU’S facing insolvency and giants like Aakash and Allen struggling with margin erosion, the market is splitting into two ends — a small group of large, well-funded players with scale and reach, and a long tail of smaller or struggling players.
Integration Challenges Loom: Despite the clear synergies between upGrad and Unacademy, the road ahead is fraught with friction. Merging two distinct corporate cultures and overlapping product lines will require brutal execution discipline. This could lead to further vertical shutdowns and staff rationalisation. On top of this, profitability pressures will only intensify as upGrad heads toward an eventual listing.
However, the consolidated entity has the potential to rewrite the country’s ailing edtech story with scale, capital discipline and product depth. With PW in the mix, is the Indian edtech ecosystem tilting towards a duopoly? Let’s find out…
Millions of Indians suffer from musculoskeletal pain, yet treatments rely heavily on medications with side effects and fleeting relief. To solve this, Hyderabad-based CURAPOD is pioneering a wearable device for drug-free, at-home pain management.
Leaning Into Light Therapy: Founded in 2022, CURAPOD is building wearable medical devices that offer personalised pain management using light-based therapies. It harnesses photobiomodulation, targeted red light wavelengths that penetrate tissues to boost cellular repair and reduce inflammation without invasive procedures.
Wearables For Everyday Pain: The startup’s flagship device claims to treat back pain, joint disorders, muscle strains and sports injuries. Unlike generic pills, CURAPOD tailors light dosage to specific conditions, delivering effects safely. Portable design fits busy lifestyles, while “clinical” backing builds trust for chronic sufferers seeking sustainable alternatives to opioids or steroids.
Eye On The Prize: The Hyderabad-based startup is eyeing a piece of the growing phototherapy equipment market, which is projected to hit $22.7 Mn by 2030 amid rising demand for non-pharma solutions for chronic pain. So, can CURAPOD turn pain management into an everyday wellness routine?
From celebrity plugs to VC cheques, India’s fragrance startups are quietly building the next big D2C category.
The post The Edtech Duopoly, Nazara’s Expansion Continues & More appeared first on Inc42 Media.
